|
CNI Stroke Program
Research & Outcomes
Clinical Trials
StELLAR: enrolling
To assess the safety and preliminary efficacy of combining intravenous tPA with transcranial laser therapy (TLT) with the NeuroThera® Laser System in subjects treated for acute ischemic stroke.
Inclusion Criteria:
Subjects will be eligible if the following criteria are met:
- Between 40 and 80 years of age
- Subject has received IV rt-PA per the NINDS rt-PA Protocol Guidelines within 3 hours of symptom onset for an acute ischemic stroke and has a documented NIHSS score of > 7 and < 17 prior to IV rt-PA administration
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from this study:
- The subject had a seizure at stroke onset or within the 7 days prior to stroke onset.
- The subject has an implant of any kind in the head (i.e. clipped aneurysm, embolised AVM, implantable shunt – Hakim valve).
Please contact Paula Fisk by e-mail or by phone at 303.806-7455.
___________________________________________
POINT: enrolling
This is a study to determine whether clopidogrel (Plavix) taken after a loading dose of 600 mg is effective in preventing major ischemic vascular events (stroke, myocardial infarction or ischemic vascular death) at 90 days when initiated within 12 hours of a TIA or minor ischemic stroke onset. Patients will also be receiving aspirin daily.
- 18 years old
- NIHSS of 3 or less
- Must be treated within 12 hours from onset of TIA/stoke symptoms
Please contact Paula Fisk by e-mail or phone 303.806.7455.
___________________________________________
IMS III: enrolling
This trial examines whether combined intravenous (IV) and intra-arterial (IA) treatment is superior to standard IV rt-PA alone when started within three hours of stroke onset.
- 18 – 82 years of age
- NIHSS of 8 of higher
- Must be able to initiate study medication within 3 hours from onset of stroke onset
Please contact Paula Fisk by e-mail or phone at 303.806.7455.
___________________________________________
DIAS-4: enrolling
A randomised, double-blind, parallel-group placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke.
- Clinical diagnosis of acute ischemic stroke
- Male or female between 18 and 85 years of age inclusive
- Treatment of the subject can be initiated within 3 – 9 hours after the onset of stroke symptoms
- NIHSS score 4-24
Please contact Paula Fisk by e-mail or phone 303.806.7455.
|
